Pirfenidone suppresses the abnormal activation of human Müller cells after platelet-derived growth factor-BB...

Area of Science:

• Ophthalmology
• Cell Biology
• Pharmacology

Background:

• Human Müller cells are crucial for retinal health.
• Platelet-derived growth factor-BB (PDGF-BB) can activate Müller cells, potentially leading to pathological conditions.
• Understanding factors that modulate Müller cell activation is vital for retinal disease research.

Purpose of the Study:

• To investigate the therapeutic effect of pirfenidone on PDGF-BB-activated human Müller cells.
• To determine pirfenidone's impact on Müller cell proliferation, migration, and collagen contraction.
• To analyze pirfenidone's influence on key molecular markers like TGF-β1, TGF-β2, and PEDF.

Main Methods:

• Primary human Müller cells were cultured and stimulated with PDGF-BB to create a pathogenic model.
• Cellular behavior was assessed using MTT assays, Trypan blue exclusion, cell migration assays, and collagen contraction assays.
• Gene and protein expression of TGF-β1, TGF-β2, and PEDF were quantified via real-time PCR, Western blot, and immunofluorescence.

Main Results:

• A reliable model of Müller cell proliferation was established using PDGF-BB stimulation.
• Pirfenidone treatment (0.2 and 0.3 mg/mL) significantly inhibited proliferation, migration, and collagen contraction in activated Müller cells.
• Pirfenidone significantly downregulated TGF-β1 and TGF-β2 expression while upregulating PEDF expression in the model group.

Conclusions:

• Pirfenidone demonstrates significant efficacy in suppressing PDGF-BB-induced human Müller cell activation.
• The mechanism involves the modulation of TGF-β and PEDF signaling pathways.
• Pirfenidone holds potential as a therapeutic agent for retinal conditions involving Müller cell dysfunction.